This study also suggests that immunotherapy, particularly inhibitors targeting the CTLA4 immune checkpoint, has significantly improved treatment outcomes for patients with advanced malignant tumors.[35,36] The relationship between SOCS1 and immune cells in glioma, which closely mirrors CTLA4 and the higher tumor mutation burden indicated by high SOCS1 expression, suggests a substantial therapeutic potential of SOCS1 in glioma. This evidence concerns the gene SOCS1 and central nervous system cancer.